2026– date –
-
USC Viterbi Engineers Develop Ultrasound-Guided SHIFTERS Technology to Reprogram Solid Tumors for CAR-T Efficacy
USC Viterbi School of Engineering USA Overview Researchers at the USC Viterbi School of Engineering have developed a novel technology called SHIFTERS to enable CAR-T cells to effectively target solid tumors. This method uses focused ultr... -
Epicrispr Raises $90M to Advance Epigenetic Editing Drug EPI-321 for Rare Muscle Disease FSHD, Completes Phase 1 Enrollment
BioPharma Dive USA Overview Epicrispr Biotechnologies has successfully raised $90 million in Series C financing to accelerate the development of EPI-321, an epigenetic editing drug for facioscapulohumeral muscular dystrophy (FSHD). EPI-3... -
Porton Advanced Secures China NMPA Drug License to Expand CDMO Services to Commercial CGT Manufacturing
Porton Advanced China Overview Porton Advanced has been granted a Class C Drug Manufacturing License by China's NMPA, enabling it to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products. This expands their... -
NueCell Bio Launches 26,300-Square-Foot Cell Therapy Development Facility to Scale CDMO Services in San Diego
PharmaSource USA Overview NueCell Bio has launched as a dedicated cell therapy science and development services company, opening a 26,300-square-foot facility in San Diego to support translational development, process development, analyt... -
Novartis’ CAR-T Cell Therapy Tisagenlecleucel Shows Durable Efficacy in Pediatric and Young Adult ALL
CancerNetwork USA Overview Novartis' CAR-T cell therapy, tisagenlecleucel (Kymriah), continues to demonstrate durable efficacy and safety in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia ... -
Groundbreaking CAR-T Cell Therapy Achievement: Multiple Myeloma Patient Attains Decade-Long Remission After Exhausting Chemotherapy Options
Stanford Medicine Facebook USA Overview A patient with advanced multiple myeloma achieved a remarkable 10-year remission after participating in a CAR-T cell therapy trial at the Fred and Pamela Buffett Cancer Center. Despite exhausting c... -
Building Commercial Readiness in Advanced Therapies: Optimizing Supply Chain, Manufacturing, and Regulatory Strategy is Critical
The Medicine Maker Unknown Overview Achieving commercial readiness for Advanced Therapy Medicinal Products (ATMPs), particularly cell and gene therapy products, is an urgent industry imperative. This requires establishing robust supply c... -
Clinical Progress of Engineered Cellular Immunotherapies for Autoimmunity: Diverse Modalities Pioneer New Treatment Avenues
PMC - NIH USA Overview Clinical development of engineered cellular immunotherapies for autoimmune diseases is rapidly advancing, poised to offer novel therapeutic options. Diverse modalities, including CAR-T cells, CAR-NK cells, and TCR-... -
Sumitomo Pharma Initiates First Patient Dosing in Phase 1/2a Trial of DSP-3077 for Schizophrenia
Clinical Trials Arena Unknown Overview Sumitomo Pharma (America) has commenced dosing the first patient in its Phase 1/2a clinical trial for DSP-3077, a novel therapeutic candidate for schizophrenia. DSP-3077 targets specific receptors r... -
Xilio Therapeutics Reports Q2 2026 Financial Results, Advances Tumor Microenvironment-Activated Immunotherapy Pipeline with Promising Early Clinical Data
GlobeNewswire USA Overview Xilio Therapeutics released its Q2 2026 financial results, reporting significant pipeline progress for its tumor microenvironment (TME)-activated immunotherapy candidates. Lead programs XTX101, XTX202, and XTX3...
